Form 4: Fractyl Health Director Receives Stock Option Grant

Director Marc Elia was granted 22,500 stock options as part of Fractyl Health's non-employee director compensation policy.

Summary

• Director Marc Elia received a grant of 22,500 stock options on June 10, 2026.
• The options have an exercise price of $0.7318 per share.
• The grant is part of the standard compensation policy for non-employee directors of Fractyl Health, Inc.
• The options are set to expire on June 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shareholders upon the potential future exercise of these options.

Risks

• Vesting is contingent upon continued service on the board of directors.

Future Outlook

The options vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants for non-employee directors are standard corporate governance practice in the biotechnology sector to attract and retain board talent.

Comparison to Industry Standards

• The grant follows standard industry practices for board compensation in small-cap biotech firms.
• The vesting schedule is consistent with typical one-year cliff vesting structures for director equity.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Fractyl Health, GUTS, Director Compensation, Stock Options, Insider Transaction, Form 4